• Aflac recently reported strong first-quarter 2026 results, highlighting solid revenue, sustained profitability, and returning about US$1.00 billion to shareholders through dividends and share repurchases.
• Alongside this, Aflac’s recognition of Dr. Heather Bittner Fagan as an Aflac Check for Cancer Champion underscores the company’s emphasis on cancer prevention and screening, reinforcing the relevance of its supplemental health products.
• Next, we’ll examine how Aflac’s robust earnings and capital returns could influence its investment narrative and future expectations.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Aflac Investment Narrative Recap

To own Aflac, you generally need to believe in the resilience of its supplemental insurance franchises in Japan and the U.S., and its ability to keep converting those cash flows into reliable capital returns. The latest first quarter 2026 results and US$1.0 billion in buybacks and dividends reinforce that story, while the biggest near term risk still looks tied to pressure in Japan and its impact on premium trends and currency exposed earnings; the Dr. Heather Bittner Fagan recognition does not materially change those fundamentals.

Among recent announcements, Aflac’s US$1.0 billion first quarter 2026 share repurchase and dividend outlay stands out because it directly links strong earnings to capital return, which matters for investors watching how the company manages softer premium trends in Japan and ongoing investment income pressure. It also frames the fireside chat at the Morgan Stanley U.S. Financials Conference as a chance for management to explain how they see earnings resilience and capital deployment evolving from here.

Yet behind the robust capital returns, investors should be aware of the ongoing drag from declining Japanese premiums and rising technology expenses...

Aflac's narrative projects $17.7 billion revenue and $3.6 billion earnings by 2029. This implies fairly flat yearly revenue growth and a $1.0 billion earnings decrease from $4.6 billion today.

Uncover how Aflac's forecasts yield a $112.07 fair value, in line with its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span about US$112 to US$168 per share, highlighting how differently some investors view Aflac’s earnings power. You should weigh those views against the current concerns around declining premiums in Japan and consider how that might affect the company’s ability to sustain its recent earnings and capital return profile.

Explore 2 other fair value estimates on Aflac - why the stock might be worth just $112.07!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Aflac research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Aflac research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aflac's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.